Showing results (191-200 of 496) with videos related to
Sort By:
Pageof 50
Clinical and Vaccine Immunology : CVI|September 18, 2015
Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by VectorizationLori F Maxfield, Peter Abbink, Kathryn E Stephenson, et al.Mbio|March 10, 2021
Viral Rebound Kinetics Correlate with Distinct HIV Antibody FeaturesYannic C Bartsch, Carolin Loos, Evan Rossignol, et al.Plos Pathogens|December 17, 2019
Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivoLawrence J Tartaglia, Alexander Badamchi-Zadeh, Peter Abbink, et al.Nature|February 1, 2022
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 OmicronJinyan Liu, Abishek Chandrashekar, Daniel Sellers, et al.Open Forum Infectious Diseases|July 16, 2016
Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral TherapyKathryn E Stephenson, George H Neubauer, Christine A Bricault, et al.Viruses|November 27, 2021
Epidemiological and Immunological Features of Obesity and SARS-CoV-2Eric J Nilles, Sameed M Siddiqui, Stephanie Fischinger, et al.JCI Insight|September 6, 2019
Predicting the broadly neutralizing antibody susceptibility of the HIV reservoirWen-Han Yu, David Su, Julia Torabi, et al.Plos One|August 25, 2018
Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challengeFreek Cox, Leslie van der Fits, Peter Abbink, et al.BMJ Open|July 6, 2019
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trialSharana Mahomed, Nigel Garrett, Edmund Capparelli, et al.Journal of Virology|July 30, 2003
Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccinesDan H Barouch, Paul F McKay, Shawn M Sumida, et al.Pageof 50